Fortitude Family Office’s Aardvark Therapeutics AARD Stock Holding History

Fortitude Family Office’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$323	Buy	+56	New	+$262	﹤0.01%	2043

Other funds holding AARD

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM

Fortitude Family Office's AARD Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 56 shares worth $323. The stake represents ﹤0.01% of the portfolio and ranks #2043 among its holdings.

12 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

Fortitude Family Office held 56 shares of Aardvark Therapeutics worth $323 as of Q2 2026.
Aardvark Therapeutics was a new Fortitude Family Office position in Q2 2026.
Aardvark Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2043 holding.
12 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.